Politics
How AI is supercharging drug development
Axios·July 20, 2026·1 min read
A TD Cowen survey of 80 biopharma leaders finds AI is compressing drug developers' preclinical costs and timelines by as much as 70%. This fuels demand for software and models to produce more experimental treatments. AI streamlines R&D before human testing begins.
Read at AxiosDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.